December 8th 2023
The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.
December 4th 2023
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
November 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
Mileham Evaluates Survival Outcomes of Immunotherapy in Extensive-Stage SCLC
November 16th 2023During a Community Case Forum event in partnership with the South Carolina Oncology Society, Kathryn Mileham, MD, discussed the significance of the IMpower133 and CASPIAN trials for patients with extensive-stage small cell lung cancer.
Read More
MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
November 14th 2023Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Watch
Updates from PAPILLON: 1L Amivantamab + Chemotherapy in Advanced NSCLC
November 14th 2023Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Alexander Spira, MD, PhD, FACP, to review data from PAPILLON, which combined amivantamab and chemotherapy as frontline treatment for patients with advanced NSCLC.
Watch
Tailoring Approaches Beyond Steroids for irAEs in Cancer Treatment
November 11th 2023For many immune-related adverse events, steroids are used as frontline treatment. However, it remains unclear if steroids allow for preservation of the antitumor immune response, resulting in the need for more options for patients with cancer.
Read More
Porter Explores Data for Sotorasib in KRAS-Mutated NSCLC
November 2nd 2023During a Targeted Oncology™ Community Case Forum event in collaboration with the Tennessee Oncology Practice Society, Jason Porter, MD, reviewed the CodeBreaK 100 and CodeBreaK 200 trials of sotorasib for patients with KRAS-mutant non–small cell lung cancer.
Read More
Mohamed Discusses Newer Chemoimmunotherapy Regimens in Squamous NSCLC
October 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mohamed K. Mohamed, MD, PhD, and participants discussed cemiplimab plus chemotherapy and tremelimumab/durvalumab plus chemotherapy as regimens for a patient with metastatic squamous non–small cell lung cancer.
Read More
EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy
October 21st 2023Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.
Read More